<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04430855</url>
  </required_header>
  <id_info>
    <org_study_id>M20-040</org_study_id>
    <nct_id>NCT04430855</nct_id>
  </id_info>
  <brief_title>A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in
      the axilla (underarm), inguinal (groin) and anogenital (anal and genital) regions. This study
      will evaluate how well upadacitinib compared to placebo (no medicine) works to treat
      hidradenitis suppurativa (HS) in adult participants with moderate to severe disease. The
      study will assess change in disease signs and symptoms.

      Upadacitinib is an investigational drug being developed for the treatment of HS. This study
      is &quot;double-blinded&quot;, which means that neither the trial participants nor the study doctors
      will know who will be given study drug and who will receive placebo (no medicine).
      Participants are randomly (by chance) put into 1 of 2 groups, called treatment arms. They are
      randomized in a 2 to 1 ratio meaning more participants have a chance to receive upadacitinib
      compared to placebo. Adult participants with a diagnosis of hidradenitis suppurativa will be
      enrolled. Around 60 participants will be enrolled in the study in approximately 28 sites
      globally.

      Participants will undergo approximately 35-days of screening followed by oral tablet
      upadacitinib or placebo once daily for 48 weeks and a 30-day follow-up visit after the last
      dose of study drug for a total study duration of up to 57 weeks.

      There may be a higher burden for participants in this trial compared to their standard of
      care. Participants will attend visits every other week, once a month, or once every 2 months
      during the course of the study at a hospital or clinic. The effect of the treatment will be
      checked by medical assessments, blood tests, checking for side effects and completing
      questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2020</start_date>
  <completion_date type="Anticipated">March 27, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 17, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR)</measure>
    <time_frame>Week 12</time_frame>
    <description>HiSCR is defined as at least a 50% reduction in the total abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to Baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Skin Pain Numeric Rating Scale 30 (NRS30)</measure>
    <time_frame>Week 12</time_frame>
    <description>The Patient's Global Assessment of Skin Pain Numeric Rating Scale (NRS) assesses the worst skin pain and the average skin pain due to HS. The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the Patient's Global Assessment of Skin Pain (NRS30) - at worst in participants with NRS &gt;=3 at Baseline are assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hidradenitis Suppurativa (HS)</condition>
  <arm_group>
    <arm_group_label>Upadacitinib Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Upadacitinib Dose A for 12 weeks (Period 1) followed by Upadacitinib Dose A for 36 weeks (Period 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by Upadacitinib Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive placebo for 12 weeks (Period 1) followed by Upadacitinib Dose B for 36 weeks (Period 2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Upadacitinib</intervention_name>
    <description>Tablet; Oral</description>
    <arm_group_label>Placebo followed by Upadacitinib Dose B</arm_group_label>
    <arm_group_label>Upadacitinib Dose A</arm_group_label>
    <other_name>RINVOQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Upadacitinib</intervention_name>
    <description>Tablet; Oral</description>
    <arm_group_label>Placebo followed by Upadacitinib Dose B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of hidradenitis suppurativa (HS) for at least 1 year prior to Baseline.

          -  Total abscess and inflammatory nodule (AN) count of &gt;= 5 at Baseline, presence of HS
             lesions in at least 2 distinct anatomical areas, and draining fistula count of &lt;=20 at
             Baseline.

          -  History of inadequate response or an intolerance to adequate trial of oral antibiotics
             for treatment of HS.

          -  Required to use a daily antiseptic wash on HS lesions.

        Exclusion Criteria:

          -  History of active skin disease (other than HS) that could interfere with assessment of
             HS, including skin infections requiring systemic treatment within 4 weeks of the
             Baseline visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Dermatology Specialist /ID# 221084</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006-2722</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences /ID# 218404</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medderm Associates /ID# 218317</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>George Washington Univ Med /ID# 218314</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skin Care Research, LLC /ID# 218809</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486-2269</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lakes Research, LLC /ID# 218854</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research /ID# 218013</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613-1244</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northshore University Health System-Evanston /ID# 218319</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin, LLC /ID# 218310</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center /ID# 218306</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-5400</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University-School of Medicine /ID# 218331</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Psoriasis Treatment Ctr NJ /ID# 218330</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center /ID# 218526</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center /ID# 218326</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southside Dermatology /ID# 218321</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135-5618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh MC /ID# 218329</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina /ID# 218318</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies /ID# 218307</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists of Spo /ID# 218760</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Institute Inc. /ID# 218780</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T1Y 0B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winnipeg Clinic, Manitoba, CA /ID# 218963</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 1T6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NewLab Clinical Research Inc. /ID# 219106</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1C 2H5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Wei Jing Loo Medicine Prof /ID# 218779</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6H 5L5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc. /ID# 218778</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Takagi Dermatological Clinic /ID# 218587</name>
      <address>
        <city>Obihiro-shi</city>
        <state>Hokkaido</state>
        <zip>080-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Kyoto Prefectural University of Medicine /ID# 220859</name>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <zip>6028566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital /ID# 218588</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cruz-Santana, Carolina, PR /ID# 221188</name>
      <address>
        <city>Carolina</city>
        <zip>00985</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Japan</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 11, 2020</study_first_submitted>
  <study_first_submitted_qc>June 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hidradenitis suppurativa (HS)</keyword>
  <keyword>Upadacitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Upadacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

